FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease ...
Investor's Business Daily on MSN
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests
Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its ...
Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study.
Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
“The approval today of KYGEVVI® (doxecitine and doxribtimine), provides real hope for patients and families living with this devastating disease,” said Angela Lek, PhD, interim Chief Research Officer ...
News-Medical.Net on MSN
Smartphones match traditional methods in monitoring patients with muscular dystrophy
Stanford Medicine researchers found that a smartphone could monitor patients with two types of muscular dystrophy as well as ...
In a heartbreaking revelation, Eric Dane, known for his role as Dr. Mark Sloan on the hit series Grey's Anatomy, has shared his diagnosis of Amyotrophic Lateral Sclerosis (ALS), a debilitating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback